What question did this study set out to answer?

This study aims to evaluate the hematotoxicity and treatment efficacy of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in a prostate cancer mouse model.

Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the hematotoxicity and treatment efficacy of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in a prostate cancer mouse model.
Twenty-five male C57BL/6 mice were inoculated with RM1-PGLS cells.
Mice were treated with [225Ac]Ac-PSMA-617 or [177Lu]Lu-PSMA-617, with tumor volumes measured weekly.
Blood samples assessed blood cell counts and organ functions after treatment.
Both treatments significantly slowed tumor progression and extended survival: median survival was 70 days for [225Ac]Ac-PSMA-617 and 58 days for [177Lu]Lu-PSMA-617.
Significant reduction in tumor volumes was observed (P < 0.05).
Hematological analysis showed reductions in WBCs, RBCs, and platelets, normalizing within 35–42 days.

No takes yet. Share an insight, caveat, or question.

Randomized trial investigates treatment efficacy and hematotoxicity in prostate cancer mouse model, suggesting transient effects.

Vilangattil et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark